TrialAdvances in therapy2022

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.

Lin Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.